Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANGIODYNAMICS INC Director's Dealing 2017

May 25, 2017

32939_dirs_2017-05-25_1a9da68b-ceb7-41f1-8682-7bf9d64022df.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2017-04-26

Reporting Person: Simpson Robert Arthur (SVP/GM, Global Vascular)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 10000 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Non-Qualified Stock Option (right to buy) $16.09 2024-01-31 Common Stock (50000) Direct
Performance Right $ Common Stock (30000) Direct

Footnotes

F1: This grant of 10,000 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents 10,000 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on January 31, 2018, such that 25% of the restricted stock units will vest on each of January 31, 2018, 2019, 2020 and 2021.

F2: These stock options vest in four equal annual installments beginning on January 31, 2018, such that 25% of the options will vest on each of January 31, 2018, 2019, 2020 and 2021.

F3: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period covering the Company's fiscal years 2017, 2018 and 2019. Any shares that do not vest at the end of the performance period will be forfeited.